Value of infliximab (Remicade(®)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade(®)) is an anti-tumor necrosis factor alpha chimeric antibody that is used in the treatment of patients with rheumatoid arthritis or Crohn’s disease. Fo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Muus, Petra, Zwierzina, Heinz, Denzlinger, Claudio, Delforge, Michel, Thyss, Antoine, Selleslag, Dominik, Indrak, Karel, Ossenkoppele, Gert, de Witte, Theo
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2012
Témata:
Original Articles and Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3347667/
https://ncbi.nlm.nih.gov/pubmed/22102701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.044347
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky